Drug intelligence / Profile preview

MK-1484

Development stage: Phase 1
Lead developer: Merck
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

MK-1484 is an investigational immunotherapy drug developed by Merck Sharp & Dohme. It is designed to help the immune system fight cancer, specifically advanced or metastatic solid tumors. MK-1484 acts as an agonist of the interleukin-2 receptor beta-gamma (IL-2Rβγ), aiming to stimulate immune responses against tumor cells while minimizing non-specific T cell activation and Fc receptor engagement. The drug is currently being evaluated in Phase 1 clinical trials both as a monotherapy and in combination with pembrolizumab for patients with advanced or metastatic solid tumors.

Targets

IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on MK-1484.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-1484.

Explore the full profile